[HTML][HTML] Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
G Giaccone, A Rajan, A Berman, RJ Kelly… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
G Giaccone, A Rajan, A Berman, RJ Kelly, E Szabo, A Lopez-Chavez, J Trepel, MJ Lee…
Journal of Clinical Oncology, 2011•ncbi.nlm.nih.govPurpose Thymic epithelial tumors are rare malignancies, and there is no standard treatment
for patients with advanced disease in whom chemotherapy has failed. Antitumor activity of
histone deacetylase (HDAC) inhibitors in this disease has been documented, including one
patient with thymoma treated with the pan-HDAC inhibitor belinostat.
for patients with advanced disease in whom chemotherapy has failed. Antitumor activity of
histone deacetylase (HDAC) inhibitors in this disease has been documented, including one
patient with thymoma treated with the pan-HDAC inhibitor belinostat.
Abstract
Purpose
Thymic epithelial tumors are rare malignancies, and there is no standard treatment for patients with advanced disease in whom chemotherapy has failed. Antitumor activity of histone deacetylase (HDAC) inhibitors in this disease has been documented, including one patient with thymoma treated with the pan-HDAC inhibitor belinostat.
ncbi.nlm.nih.gov